Roland Kuiper

Senior Principal Investigator

Princess Máxima Center for Pediatric Oncology
Country flagNetherlands
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Background Rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation (ROHHAD) and neuroendocrine tumor (NET) is a very rare condition with an unknown etiology. While various potential causes have been hypothesized, including genetic and paraneoplastic autoimmune mechanisms, no definitive cause has been identified to date. This study aimed to explore whether patients with ROHHAD-NET share an underlying heritable genetic etiology. Results We identified five female patients clinically suspected of having ROHHAD(-NET); among them in two patients a NET was found: a ganglioneuroma and a low grade cerebellar ganglion cell tumor with BRAF mutation. To identify potential pathogenic germline genomic variants, whole genome sequencing (WGS) was performed on germline DNA from all five patients, including four patient-parent trios. Furthermore, optical genome mapping (OGM) was performed for two patients to detect germline structural variants (SVs). Rare single nucleotide variants (SNVs) and small insertions/deletions (InDels) were identified through WGS and rare SVs affecting (non)-coding or regulatory regions were analyzed using both WGS and OGM. We explored a de novo , inherited autosomal dominant and autosomal recessive inheritance scenario. However, no candidate variants in a recurrently affected gene locus or genomic region were identified in two or more patients. Conclusion Our comprehensive genome-wide data analysis did not reveal evidence of a monogenetic cause for ROHHAD-NET. Whereas these findings do not exclude a genetic etiology for ROHHAD-NET, they strengthen the hypothesis of an autoimmune origin for symptoms of ROHHAD.

Year:

2025

Despite compliance to surveillance colonoscopies, patients with Lynch Syndrome (LS) remain at a substantial lifetime risk of developing colorectal cancer, with rates as high as 30–52%. This highlights the need for better cancer prevention strategies. To assess the safety, feasibility, and immunogenicity of a preventive (neo)antigen-based dendritic cell (DC) vaccine, a phase I/II clinical trial was conducted involving 3 LS patients with a recent history of colorectal cancer (CRC) and 20 cancer free LS patients. All participants were HLA-A2 + and received autologous mature DC pulsed with HLA-A2-binding short peptide derived from carcinoembryonic antigen (CEA) and frameshift-derived neoantigens from caspase-5 and TGF-βRII. No grade 4 adverse events occurred in 22/23 patients and (neo)antigen-specific CD8 T cells were detected in nearly all patients. Post-vaccination, patients who developed T cells specific for the TGF-βRII neoantigen (39%) did not develop any LS-associated neoplasia with TGFBR2 mutation and have remained cancer-free for nearly 10 years. (ClinicalTrials.gov identifier- NCT01885702)

Year:

2025

Children harboring certain germline gene variants have an increased risk of developing myelodysplastic syndrome (MDS) and other hematopoietic malignancies (HM), such as leukemias and lymphomas. Recent studies have identified an expanding number of these predisposition genes, with variants most prevalent in children with MDS but also found in children with other HM. For some hematopoietic malignancy predispositions (HMP), specifically those with a high risk of MDS, early intervention through hematopoietic stem cell transplantation can favorably impact overall survival, providing a rationale for rigorous surveillance. A multidisciplinary panel of experts at the 2023 AACR Childhood Cancer Predisposition Workshop reviewed the latest advances in the field and updated prior 2017 surveillance recommendations for children with HMP. In addition to general guidance for all children with HMP, which includes annual physical examination, education about the signs and symptoms of HM, consultation with experienced providers, and early assessment by a hematopoietic stem cell transplantation specialist, the panel provided specific recommendations for individuals with a higher risk of MDS based on the affected gene. These recommendations include periodic and comprehensive surveillance for individuals with those syndromes associated with higher risk of MDS, including serial bone marrow examinations to monitor for morphologic changes and deep sequencing for somatic changes in genes associated with HM progression. This approach enables close monitoring of disease evolution based on the individual’s genetic profile. As more HMP-related genes are discovered and the disorders’ natural histories are better defined, these personalized recommendations will serve as a foundation for future guidelines in managing these conditions.

Year:

2024

Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.

Year:

2024

Collaborators (18)

Sharon E. Plon

Professor and Assistant Dean

Baylor College of Medicine

UNITED STATES
View details

Margreet A Veening

University of Amsterdam

NETHERLANDS
View details

Alison Bertuch

Professor

Baylor College of Medicine

UNITED STATES
View details

Sharon Savage

Clinical Director

National Cancer Institute

UNITED STATES
View details

Lisa J. McReynolds

National Institutes of Health

UNITED STATES
View details

Carl Figdor

University of Twente

NETHERLANDS
View details

Marcin W Wlodarski

PI

St. Jude Children's Research Hospital

UNITED STATES
View details

Luke D. Maese

Huntsman Cancer Institute

UNITED STATES
View details

Vivian Y. Chang

University of California

UNITED STATES
View details

Kim Erika Nichols

Full Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Gaëlle Bougeard

University of Rouen

FRANCE
View details

Christopher C. Porter

Emory University School of Medicine

UNITED STATES
View details

Lucy A. Godley

Northwestern Medicine

UNITED STATES
View details

I. Jolanda M. de Vries

Department head

Radboudumc

NETHERLANDS
View details

Iris Nagtegaal

Professor of Gastrointestinal Pathology

Radboudumc

NETHERLANDS
View details

Sarah Scollon

Assistant Professsor/Genetic Counselor

Baylor College of Medicine

UNITED STATES
View details

Julia Meade

Associate Professor of Pediatrics

West Virginia University

UNITED STATES
View details

Hamish Scott

University of South Australia

AUSTRALIA
View details